Thus, Welch and coworkers have shown that 10-day cycles of decitabine induced clinical responses in 21 of 21 patients with TP53 mutations, and these patients had equivalent outcomes compared with TP53 non-mutated AMLs: in both AML groups, the median overall survival was around 500 days [377]. Here, TP53 is linked to acute myeloid leukemia.